Middle-aged and older people taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs) such as Ozempic or Mounjaro for type 2 diabetes and obesity could be less likely to develop dementia or have a stroke, according to international research. The team followed 60,000 adults aged 40+ for about seven years, half of whom were taking a GLP-1 RA, with the other half on other antidiabetic drugs. By the end of the study, the researchers say the GLP-1 RA group were less likely to have developed dementia, had a stroke or died of any cause. They say this means this class of drugs could come with benefits for brain health.
Journal/conference: JAMA Network Open
Research: Paper
Organisation/s: Chang Gung Memorial Hospital, Taiwan
About The Study: In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. These findings suggest potential neuroprotective and cerebrovascular benefits of GLP-1RAs beyond glycemic control, warranting further trials to confirm these outcomes.
Note: Not all attachments are visible to the general public
